Infect Immun 2007, 75:371–378.PubMedCrossRef 11. Piddock LJ: Multidrug-resistance efflux pumps – not just for resistance. Nat Rev Microbiol 2006, 4:629–636.PubMedCrossRef 12. Gil H, Platz GJ, Forestal CA, Monfett M, Bakshi CS, Sellati TJ, Furie MB,

Benach JL, Thanassi DG: Deletion of TolC orthologs in Francisella tularensis identifies roles in multidrug resistance and virulence. Proc Natl Acad Sci USA 2006, 103:12897–12902.PubMedCrossRef 13. Kobayashi N, Nishino K, Yamaguchi A: Novel macrolide-specific ABC-type efflux transporter in Escherichia coli. J Bacteriol 2001, 183:5639–5644.PubMedCrossRef 14. Chollet R, Chevalier J, Bryskier A, Pages JM: The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin MG-132 datasheet efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 2004, 48:3621–3624.PubMedCrossRef

15. Bina XR, Lavine CL, Miller MA, Bina JE: The AcrAB RND efflux system from the live vaccine strain of Francisella tularensis is a multiple drug efflux system selleck inhibitor that is required for virulence in mice. FEMS Microbiol Lett 2008, 279:226–233.PubMedCrossRef 16. Qin A, Scott DW, Mann BJ: Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence. Infect Immun 2008, 76:3086–3092.PubMedCrossRef 17. Ferwerda A, Moll HA, Hop WC, Kouwenberg JM, Tjon Pian Gi CV, Robben SG, de Groot Pyruvate dehydrogenase lipoamide kinase isozyme 1 R: Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. J Antimicrob Chemother 2001, 47:441–446.PubMedCrossRef 18. Amsden GW: selleck products Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 2001,18(Suppl 1):S11–15.PubMedCrossRef 19. Lai XH, Sjostedt A: Delineation of the molecular mechanisms of Francisella tularensis-induced apoptosis in murine macrophages. Infect Immun 2003, 71:4642–4646.PubMedCrossRef 20. Telepnev M, Golovliov

I, Sjostedt A: Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells. Microb Pathog 2005, 38:239–247.PubMedCrossRef 21. Baron GS, Nano FE: MglA and MglB are required for the intramacrophage growth of Francisella novicida. Mol Microbiol 1998, 29:247–259.PubMedCrossRef 22. Hall JD, Craven RR, Fuller JR, Pickles RJ, Kawula TH: Francisella tularensis replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation. Infect Immun 2007, 75:1034–1039.PubMedCrossRef 23. Han S, Bishop BM, van Hoek ML: Antimicrobial activity of human beta-defensins and induction by Francisella. Biochem Biophys Res Commun 2008, 371:670–674.PubMedCrossRef 24. Craven RR, Hall JD, Fuller JR, Taft-Benz S, Kawula TH: Francisella tularensis invasion of lung epithelial cells.